Atrial fibrillation: the cost of illness in Sweden

Ericson, Lisa; Bergfeldt, Lennart; Björholt, Ingela

doi:10.1007/s10198-010-0261-3

Cited by 46 publications

(45 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In patients invited to systematic screening, 53% registered ECG, and a new AF diagnosis was noted in 52/2357 (2%). The UK study from Fitzmaurice et al 35 lacks data on OAC treatment, both in patients with known AF and in patients newly diagnosed with AF. Data on OAC is of importance for calculations of cost effectiveness because the majority of costs for AF stem from stroke care.…”

Section: Af Prevalencementioning

confidence: 99%

Stepwise Screening of Atrial Fibrillation in a 75-Year-Old Population

et al. 2013

View full text Add to dashboard Cite

Background-Atrial fibrillation (AF) is a frequent source of cardiac emboli in patients with ischemic stroke. AF may be asymptomatic and therefore undiagnosed. Screening for silent AF seems suitable in risk populations, however little is known on the yield and cost-effectiveness of such screening. Methods and Results-All inhabitants in the municipality of Halmstad, Sweden aged 75 to 76 years were invited to a stepwise screening program for AF. As a first step, participants recorded a 12-lead ECG and reported their relevant medical history. Those with sinus rhythm on 12-lead ECG, no history of AF, and ≥2 risk factors according to CHADS 2 were invited to a 2-week recording period using a hand-held ECG and asked to record 20 or 30 seconds twice daily and if palpitations occurred. One thousand, three hundred thirty inhabitants were invited, of whom 848 (64%) participated. Previously undiagnosed silent AF was found in 10 (1%)

show abstract

Section: Af Prevalencementioning

confidence: 99%

Stepwise Screening of Atrial Fibrillation in a 75-Year-Old Population

et al. 2013

View full text Add to dashboard Cite

show abstract

“…As a comparison, it has been estimated that the total cost of all gastrointestinal illnesses in Sweden amount to approximately €1 billion, based on a cohort study with 3241 participants [58]. Annual COI estimates have also been reported for other illnesses in Sweden, such as rheumatoid arthritis (€600 million) [59], breast cancer (€330 million) [60] and atrial fibrillation (€708 million) [61]. The estimations of the true number of cases of each illness were calculated by multiplying the number of reported cases by a pathogen-specific MF.…”

Section: Discussionmentioning

confidence: 99%

A Systematic and Critical Review of Model-Based Economic Evaluations of Pharmacotherapeutics in Patients with Bipolar Disorder

Mohiuddin

2014

Appl Health Econ Health Policy

View full text Add to dashboard Cite

Objectives The main objective of this study was to derive cost estimates of five major foodborne illnesses (campylobacteriosis, salmonellosis, enterohemorrhagic Escherichia coli (EHEC), yersiniosis and shigellosis) in Sweden. These estimates provide a necessary contribution to perform future cost-benefit analyses aimed at reducing the burden of foodborne disease. A secondary aim was to obtain estimates of the true number of cases that occur in the community, thus providing necessary ground for calculating costs. Methods The true number of cases for each foodborne illness was simulated by multiplying the reported number of cases by sequential multipliers, one for each potential source of information loss about a case. This assessment of the true number of cases was then used to estimate the number of cases of sequelae for each illness. An incidence-based analysis was then used to calculate direct medical and non-medical costs, as well as indirect costs. Data for estimating the true number of cases for each illness were primarily based on an expert panel, while the derivation of costs mainly utilized national registries, databases and published literature. Results The estimated number of cases was between 7-and 11-fold higher than the reported number of cases, indicating the importance of taking information loss into account when calculating costs. By far the most common pathogen of the five was campylobacter, with an estimated 101,719 (90% credibility interval [CI] 59,640-158,025) human cases occurring annually. For salmonella, 19,678 (90% CI 8394-40,456) cases were estimated to occur each year, while the other three pathogens were less common, with a yearly incidence of approximately 2500-5500 cases each. The total cost for the five pathogens (including sequelae) amounted to €142 million annually. Campylobacter was the most costly pathogen, representing 69% of the total costs. Salmonellosis and EHEC constituted 18 and 9% of these costs, respectively, while yersiniosis and shigellosis represented approximately 2% each. Costs for sequelae were significant and accounted for approximately 50% of the total costs. Conclusions Our simulations indicated that campylobacter infection was more common and more costly than salmonella, EHEC, yersinia and shigella combined. Estimated costs for all illnesses were highly influenced by (1) considering potential information losses about cases in the population (which increased costs 7-to 11-fold), and (2) taking account of postinfection sequelae (which doubled the costs). Key Points for Decision MakersThis study estimates the difference between registered and actual number of cases in the community for five major foodborne diseases. Potential post-infection sequelae are included in the analysis. These considerations are crucial in order to assess the actual societal burden of the five pathogens.The study also estimates total societal costs and costs per case for the five pathogens, results that can be utilized in future cost-benefit or cost-effectiveness studies.

show abstract

“…As principais complicações da FA são a insuficiência cardíaca e o AVC isquémico, sendo este último a complicação mais grave 28,29 . A relação entre a FA e o AVC é inequívoca: os doentes com FA têm um risco ajustado para a idade cinco vezes superior ao da população em geral 30 .…”

Section: Custos Da Doençaunclassified